8-K: Acurx Pharmaceuticals Announces Positive Phase 2b Trial Results and Provides Financial Update

Acurx Pharmaceuticals reported positive results from its Phase 2b clinical trial for ibezapolstat, showing high cure rates for C. difficile infection, and provided a financial update including a cash balance of $7.5 million at the end of 2023.

Summary

• Acurx Pharmaceuticals announced its fourth quarter and full year 2023 financial results and provided a business update.
• The company's lead antibiotic candidate, ibezapolstat, demonstrated a 96% clinical cure rate at the end of 10 days of oral treatment in its Phase 2b clinical trial.
• The Phase 2b trial was terminated early due to success, showing high observed clinical cure rates with no emerging safety concerns.
• Sustained clinical cure data showed 100% of patients cured at the end of treatment remained cured 30 days later, compared to a 14.3% reinfection rate with vancomycin.
• Ibezapolstat outperformed vancomycin in eradicating fecal C. difficile at Day 3 of treatment, with 94% eradication compared to 71% for vancomycin.
• The company submitted an Information Package to the FDA in February 2024 and has scheduled an End of Phase 2 Meeting in April 2024.
• Acurx ended 2023 with $7.5 million in cash, compared to $9.1 million at the end of 2022.
• Subsequent to year-end, the company raised an additional $4.5 million through its at-the-market equity offering program.
• Research and development expenses for 2023 were $6.0 million, up from $4.8 million in 2022.
• General and administrative expenses for 2023 were $8.5 million, compared to $7.3 million in 2022.
• The company reported a net loss of $14.6 million for the year ended December 31, 2023, compared to a net loss of $12.1 million in 2022.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for ibezapolstat, which is a significant positive for the company. The financial results show increased losses and reduced cash, but the successful capital raise and progress towards Phase 3 trials are encouraging. The overall sentiment is positive, reflecting the potential of the drug candidate.

Positives

• The Phase 2b clinical trial of ibezapolstat demonstrated a high clinical cure rate of 96%.
• Ibezapolstat showed a 100% sustained cure rate at 30 days post-treatment.
• Ibezapolstat outperformed vancomycin in eradicating C. difficile and preserving the gut microbiome.
• The company has a scheduled End of Phase 2 Meeting with the FDA in April 2024.
• The company received SME designation from the EMA, which provides benefits such as fee reductions.
• The company successfully raised additional capital through its ATM program after year end.

Negatives

• The company experienced a net loss of $14.6 million for the year ended December 31, 2023.
• The company's cash position decreased from $9.1 million at the end of 2022 to $7.5 million at the end of 2023.
• Research and development expenses increased to $6.0 million in 2023 from $4.8 million in 2022.
• General and administrative expenses increased to $8.5 million in 2023 from $7.3 million in 2022.

Risks

• The company's future success depends on the successful completion of Phase 3 clinical trials for ibezapolstat.
• There is a risk that ibezapolstat may not receive regulatory approval from the FDA or other regulatory agencies.
• The company's ability to commercialize ibezapolstat depends on its ability to secure funding and establish a distribution network.
• The company's financial performance is subject to risks associated with drug development and commercialization.
• The company is reliant on the success of a single drug candidate.

Future Outlook

The company anticipates discussing its Phase 3 clinical trial mandate at the upcoming End of Phase 2 meeting with the FDA and expects documented meeting minutes in the second quarter of 2024. The company also expects to use proceeds from the ATM offering for general corporate purposes, including the planned Phase 3 clinical trial.

Management Comments

• David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update.
• The company anticipates that additional data from the secondary and exploratory endpoints will provide further favorable separation between ibezapolstat and vancomycin in the Phase 3 clinical trial program.

Industry Context

The development of new antibiotics is critical due to the increasing threat of antibiotic-resistant bacteria, such as C. difficile. Acurx's ibezapolstat, with its novel mechanism of action and selective spectrum, addresses this need and could potentially offer a significant improvement over existing treatments like vancomycin. The company's focus on preserving the gut microbiome is also aligned with current trends in antibiotic development.

Comparison to Industry Standards

• The 96% clinical cure rate for ibezapolstat in the Phase 2b trial is very promising and compares favorably to the cure rates of existing treatments for C. difficile infection, such as vancomycin and fidaxomicin.
• The 100% sustained cure rate at 30 days post-treatment is a significant advantage over vancomycin, which had a 14.3% reinfection rate in the same trial.
• The microbiome data showing that ibezapolstat preserves key gut bacteria is a differentiating factor compared to broad-spectrum antibiotics, which can disrupt the gut microbiome and lead to adverse effects.
• The company's progress in advancing ibezapolstat to Phase 3 trials is in line with the typical development timeline for new antibiotics, but the company is still in the early stages of commercialization compared to established pharmaceutical companies.

Stakeholder Impact

• Shareholders will be impacted by the positive clinical trial results and the potential for future revenue from ibezapolstat.
• Employees will be impacted by the company's progress and the potential for growth.
• Patients with C. difficile infection will benefit from the development of a new and effective treatment option.
• The company's suppliers and creditors will be impacted by the company's financial performance and future growth.

Next Steps

• The company will discuss its Phase 3 clinical trial mandate at the End of Phase 2 Meeting with the FDA in April 2024.
• The company anticipates receiving documented meeting minutes from the FDA in the second quarter of 2024.
• The company will continue to analyze data from the Phase 2b trial and provide updates on secondary and exploratory endpoints.
• The company will use proceeds from the ATM offering to fund general corporate purposes, including the planned Phase 3 clinical trial.

Key Dates

Keywords

ibezapolstat, C. difficile, antibiotic, clinical trial, Phase 2b, FDA, microbiome, vancomycin, cure rate, financial results, at-the-market offering, ACXP